NasdaqGS - Delayed Quote • USD
Editas Medicine, Inc. (EDIT)
At close: 4:00 PM EDT
After hours: 6:19 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 15 | 15 |
| Avg. Estimate | -0.67 | -0.67 | -2.66 | -2.74 |
| Low Estimate | -1.09 | -1.11 | -3.83 | -4.51 |
| High Estimate | -0.44 | -0.46 | -1.84 | -1.72 |
| Year Ago EPS | -0.71 | -0.56 | -2.02 | -2.66 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 15 | 15 |
| Avg. Estimate | 7.9M | 6M | 35.66M | 26.48M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 27.5M | 14.7M | 78.7M | 53.86M |
| Year Ago Sales | 9.85M | 4.17M | 78.12M | 35.66M |
| Sales Growth (year/est) | -19.80% | 43.90% | -54.40% | -25.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.78 | -0.76 | -0.57 | -0.54 |
| EPS Actual | -0.71 | -0.56 | -0.55 | -0.23 |
| Difference | 0.07 | 0.2 | 0.02 | 0.31 |
| Surprise % | 9.00% | 26.30% | 3.50% | 57.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.67 | -0.67 | -2.66 | -2.74 |
| 7 Days Ago | -0.67 | -0.67 | -2.66 | -2.74 |
| 30 Days Ago | -0.67 | -0.67 | -2.66 | -2.74 |
| 60 Days Ago | -0.6 | -0.59 | -2.35 | -2.34 |
| 90 Days Ago | -0.59 | -0.58 | -2.38 | -2.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EDIT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 5.60% | -- | -- | 1.50% |
| Next Qtr. | -19.60% | -- | -- | 11.40% |
| Current Year | -31.70% | -- | -- | 5.20% |
| Next Year | -3.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 1.70% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 2/29/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 2/29/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 2/27/2024 |
| Maintains | Truist Securities: Buy to Buy | 12/12/2023 |
| Upgrade | Citigroup: Neutral to Buy | 10/24/2023 |
| Upgrade | JP Morgan: Underweight to Neutral | 10/18/2023 |
Related Tickers
NTLA Intellia Therapeutics, Inc.
21.17
-1.67%
BEAM Beam Therapeutics Inc.
22.74
-3.11%
CRSP CRISPR Therapeutics AG
55.65
-1.35%
CRBU Caribou Biosciences, Inc.
3.8500
-3.27%
VERV Verve Therapeutics, Inc.
6.58
-4.36%
BLUE bluebird bio, Inc.
0.9229
-4.91%
DNA Ginkgo Bioworks Holdings, Inc.
0.8458
-2.84%
DTIL Precision BioSciences, Inc.
9.82
-4.01%
RXRX Recursion Pharmaceuticals, Inc.
7.94
+3.12%
ABCL AbCellera Biologics Inc.
3.9000
-1.76%